Your new post is loading...
Precision-controlled CAR-T-cell immunotherapies could be used to tackle a range of tumour types.
Via BigField GEG Tech
|
Rescooped by Gilbert C FAURE from Genetic Engineering Publications - GEG Tech top picks |
Scoop.it!
Via BigField GEG Tech
Researchers have bolstered the power of chimeric antigen receptor (CAR)-T cancer therapies, which use genetically altered T cells to seek out tumours and mark them for destruction. Now scientists have further engineered the cells to contain switches that allow control over when and where the cells are active. This helps them to infiltrate tumours and dodge immune-suppressing defences.